Anovate

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anovate

Property Description
Active Ingredients Lidocaine, Beclometasone, Phenylephrine
Form Topical Preparation (e.g., Cream, Ointment, or Suppository)
Pharmacological Class Compound Anesthetic, Anti-inflammatory, Vasoconstrictor Agent
Route of Administration Topical Route
Origin Synthetic

Anovate: Defining the Multi-Modal Composition and Type

Anovate is defined as a topical combination medication, a specific formulation developed to provide comprehensive local relief, which places it in a distinct pharmacological category. It is classified as a compound agent possessing anesthetic, anti-inflammatory, and vasoconstrictive properties. Unlike single-ingredient topical products, this preparation utilizes a multi-modal action designed to simultaneously address the painful, swollen, and irritated symptoms associated with anorectal discomfort. This targeted combination represents a focused therapeutic strategy for managing acute symptoms at the site of application.

What Active Ingredients Define the Preparation?

The formulation's core identity is established by its three primary active ingredients, all of synthetic origin, suspended in a pharmaceutical base for topical route administration. These components are Lidocaine Hydrochloride, a potent local anesthetic acknowledged for blocking nerve signals, Beclometasone Dipropionate, a powerful glucocorticoid for localized inflammation, and Phenylephrine Hydrochloride, which functions as a vasoconstrictor. The specific blend of these pharmacological classes distinguishes the Anovate preparation, providing a uniquely integrated approach compared to single or dual-component options.

General Purpose: What is the Overall Benefit of Anovate?

The overall benefit of Anovate is the simultaneous mitigation of key symptoms, aimed at delivering rapid, localized comfort. By combining a local anesthetic, a potent anti-inflammatory agent, and a vasoconstrictor, the medication utilizes a highly coordinated approach to break the cycle of acute discomfort more effectively than products relying on a single active component. Its typical, neutral use scenario involves providing symptomatic relief for the temporary pain and swelling associated with anorectal conditions. This integrated effect means the formulation's design focuses solely on achieving prompt, effective local comfort through topical use.

Regulatory References

  1. Phenylephrine Hydrochloride

What side effects are possible with Anovate?

Possible Side Effects and Safety Information

The officially documented safety profile of this topical combination medication is characterized by localized adverse reactions and the rare potential for systemic effects from its active components (Lidocaine, Beclometasone, and Phenylephrine).

According to regulatory classification standards, adverse reactions are grouped by frequency and the body system affected. The most frequently reported effects are generally localized to the application site.


Official Adverse Reaction Categories

  • Common Effects: Localized reactions such as a burning sensation, stinging, itching (pruritus), and irritation at the site of application are classified as common. These effects are often most noticeable at the beginning of treatment.
  • System-Organ Classes Involved: Adverse effects are documented across multiple systems, including Skin and Subcutaneous Tissue Disorders (e.g., irritation, atrophy) and, rarely, Nervous System Disorders (e.g., dizziness, drowsiness), Cardiac Disorders (e.g., tachycardia, palpitations), and Endocrine Disorders (e.g., adrenal suppression).
  • Serious Adverse Reactions: The regulatory label documents the potential for serious, though rare, reactions such as Adrenal Suppression and Systemic Local Anesthetic Toxicity (affecting the central nervous system or cardiovascular function), primarily associated with excessive or prolonged systemic exposure.

Safety Considerations and Limitations

The risk of certain effects is officially noted to be time- or duration-related. The risk of skin atrophy or systemic effects from the corticosteroid component increases with prolonged or extensive use.

Population-specific safety considerations include an increased risk of systemic toxicity in pediatric patients due to their higher surface area-to-weight ratio. Additionally, patients with hepatic impairment may be at greater risk of systemic Lidocaine exposure. Safety documentation restricts use in areas with untreated infections and highlights caution in patients with certain pre-existing cardiovascular conditions due to the Phenylephrine component.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from this topical preparation is primarily due to the systemic absorption of the Lidocaine and Phenylephrine components, resulting in serious toxicity. Documented manifestations may affect the Central Nervous System (CNS), initially presenting as lightheadedness, confusion, dizziness, tinnitus, or a metallic taste. Progression can lead to severe neurological outcomes including seizures, slurred speech, coma, and respiratory arrest.

Cardiovascular toxicity is also an official concern, manifesting as bradycardia, hypotension, or a significant rise in blood pressure, potentially leading to cardiac arrest or cardiovascular collapse. A documented acute complication is Methemoglobinemia, identifiable by cyanotic skin discoloration (pale, gray, or blue-colored skin), which requires immediate intervention.

Regulatory documents explicitly state that users must seek immediate medical attention if any signs of systemic toxicity or Methemoglobinemia are observed. This is required because overdose may necessitate specialized procedural steps, such as symptomatic treatment, supportive care, continuous physiological monitoring, and the use of specific reversal agents like Methylene Blue or Lipid Emulsion therapy. Furthermore, individuals with severe hepatic disease or those at the extremes of age are recognized in regulatory labeling as being at increased risk for toxic blood concentrations.

Therapeutic Uses of Anovate

The formulation is used in the symptomatic management of anorectal disorders. It is applied across domains where additional symptomatic support is needed.

This medication is used in situations involving certain distressing symptoms associated with conditions such as haemorrhoids (piles), anal fissures, and minor degrees of proctitis. It is relevant for managing symptom clusters that may become intense or disruptive, such as localized pain, swelling, and inflammation.

“The medication’s role is to provide support during episodic manifestations of discomfort.”

It is relevant for managing symptoms that interfere with daily comfort, and may assist with easing the overall symptom load during acute episodes, applied in clinical settings that involve post-haemorrhoidectomy pain. The formulation contributes to easing the overall symptom load and supports general well-being during symptomatic phases.


Quick Fact: Relief for Acute Localized Pain and Swelling

Regulatory References

  1. Nigerian Regulatory Authority (NAFDAC)

Eligibility and Restrictions for Use

Who Can and Cannot Use Anovate?

This section outlines the officially documented eligibility rules and restrictions based strictly on governmental regulatory prescribing information.

Contraindicated Populations

Use of this preparation is strictly prohibited for individuals with a known hypersensitivity to any of its components (Lidocaine, Beclometasone, Phenylephrine) or excipients. Absolute contraindications apply to patients with specific local conditions, including active viral, fungal, or bacterial infections of the skin, as well as perianal ulcers or open wounds. The medicine must not be used concurrently by patients taking Monoamine Oxidase Inhibitors (MAOIs).

Conditional Eligibility and Restrictions

The regulatory profile defines several populations requiring caution:

  • Conditional Use: Caution is advised for patients with systemic conditions such as impaired hepatic function, cardiovascular disease (e.g., hypertension or bradycardia), diabetes mellitus, and hyperthyroidism, due to the risk of systemic absorption.
  • Age Rules: The product is not recommended for children below 12 years of age because official safety and efficacy data have not been established in this group. Infants younger than 6 months and elderly patients carry an increased risk of methemoglobinemia.
  • Pregnancy and Lactation: Use during these periods is permitted with caution but should not be extensive (large amounts or prolonged periods).

What should I know about interactions with other medicines?

Anovate Interactions with other medicines and products

Since Anovate is a topical preparation, the potential for drug interactions is generally considered lower than with oral medications. However, the active components—Beclomethasone (corticosteroid), Phenylephrine (vasoconstrictor), and Lignocaine/Lidocaine (local anesthetic)—carry known interaction risks that may be relevant if significant systemic absorption occurs, particularly with prolonged or excessive use.

Product Category Interacting Medicines Explicitly Listed Interaction Mechanism and Constraint
Anticoagulants (Blood Thinners) Warfarin, Heparin Phenylephrine component can constrict blood vessels, potentially affecting the action of these medicines. Use cautiously.
Antihypertensives (Blood Pressure Medicines) Amlodipine, Lisinopril Phenylephrine may cause an increase in blood pressure, which could counteract the effect of these medicines. Use with caution.
Antiarrhythmics (Heart Rate Medicines) Tocainide, Mexiletine, Amiodarone Lignocaine/Lidocaine may aggravate the effect of these medicines on the heart, potentially leading to a decrease in heart rate.

Interaction-Related Restrictions

Patients with pre-existing conditions such as Hypertension (high blood pressure) or certain Heart Diseases should use Anovate cautiously due to the vasoconstrictive effect of phenylephrine. Furthermore, the cream should not be applied to an existing skin infection in the area unless a concurrent antibiotic treatment has been prescribed by a doctor, due to the corticosteroid component. Consult a healthcare professional about all current medications, including over-the-counter products and supplements.

Mechanism of Action

The mechanism of action involves a coordinated, multi-modal intervention across three distinct physiological domains, targeting the core systems responsible for initiating and maintaining local nociceptive, vascular, and inflammatory processes. The multi-modal action involves distinct molecular-level interactions that result in altered physiological processes.

Modulating Local Nerve Signaling

The anesthetic mechanism focuses on peripheral sensory nerve cells, executing a use-dependent blockade of voltage-gated sodium channels (NaV). By inhibiting the influx of sodium ions essential for neuronal depolarization, the drug stabilizes the nerve membrane and prevents the initiation and propagation of the electrical impulse. This specific interaction with the nociceptive signaling pathway contributes to the cessation of local sensory signal propagation.

Regulating Vascular Tone and Congestion

The vasoconstrictor component acts as a direct agonist at the Alpha-1 (alpha1) Adrenergic Receptors located on the smooth muscle of local blood vessels. This receptor activation triggers a signaling cascade that forces the vascular smooth muscle to contract, resulting in vasoconstriction. The physiological outcome is a decrease in local blood flow and hydrostatic pressure, which results in reduced tissue volume and congestion.

Suppressing Inflammatory Cascades

The steroid component's agonism at the Glucocorticoid Receptor (GR) leads to the nuclear transrepression of pro-inflammatory transcription factors, notably NF-kappaB, and the modulation of gene expression. This dual action suppresses the biochemical synthesis and release of potent inflammatory mediators (e.g., prostaglandins and cytokines), resulting in the modulation and reduction of the local inflammatory cascade.

Dosage and Administration Information

Instruction Map: How to use Anovate — Administration Guidelines

This section outlines the high-level principles for using the Anovate preparation (Lidocaine, Beclometasone, Phenylephrine).

Administration Scope

Feature Guideline
Route of administration Topical Route (External application) and Intra-anal/Rectal Route (Internal application using a dedicated applicator).
Dosing schedule Application of a small amount or a thin layer sufficient to cover the affected area, with dose defined qualitatively by coverage.
Age-group administration rules The preparation is not recommended for use in children under 12 years of age.
Missed-dose rules If an application is missed, a double dose must not be applied to compensate.

Instruction Classifications (High-Level)

Classification Description
Frequency pattern Variable Daily Use: Up to two to three times per day initially, then reduced to once daily as symptoms subside.
Use-context constraints Short-Term Use Constraint: The duration of continuous use is typically restricted to a maximum of 14 consecutive days.

Resulting Procedural Structure

Standardized step sequence:

  • The application site must be cleaned and dried prior to preparation use.
  • Apply the thin layer of medication sparingly, using the applicator for internal administration.
  • Begin with the higher frequency (two to three times daily) during acute symptomatic periods.
  • Reduce the frequency to once daily when initial symptoms have stabilized.

Connection to the overall use protocol (2–4 sentences): The instructions establish a standardized protocol that dictates the variable frequency based on the stage of discomfort and enforces a short-term maximum duration of 14 days. This protocol specifies the approved topical and intra-anal routes and mandates the use of a qualitative dose (a small amount) applied only to patients meeting the minimum age requirement of 12 years.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anovate

This section describes the types of research and clinical evaluations that have been conducted for combination topical preparations like Anovate, which includes anesthetic, anti-inflammatory, and vasoconstrictor components. This overview focuses on the documented evidence base and what official sources report, without providing treatment guidance or recommendations.


Evidence for Symptomatic Relief of Haemorrhoids

Research examining the use of multi-component topical agents has been applied in studies examining patient-reported experiences of discomfort related to haemorrhoidal disease. These investigations often take the form of short-term Randomized Controlled Trials (RCTs) or systematic reviews that consolidate data from multiple clinical settings. Research examined how symptoms, which are often characterized by fluctuating or episodic manifestations, were measured over a defined time interval.

Studies primarily monitored outcomes related to physical discomfort, specifically examining changes in patient-reported outcomes describing perceived discomfort and pain scores, along with clinical observation of localized swelling and inflammation. These populations were adults experiencing heightened symptom activity associated with internal haemorrhoidal disease (typically Grade I to Grade III).


Research on Anal Fissures and Minor Proctitis Symptoms

Studies explored the use of this preparation in the context of conditions like anal fissures and minor inflammation of the rectal lining. The evidence base here is relevant in trials assessing short-term or episodic symptom patterns and is often drawn from studies focused on the individual active components (the local anesthetic and the anti-inflammatory agent).

The studies monitored outcomes linked to inflammatory or irritative states and focused on the measurement of localized pain. Research generally focused on adult populations who presented with conditions associated with acute or disruptive episodes. Comparative evidence for this specific triple combination formulation is often lacking when compared to other treatment strategies for the underlying condition.


Duration of Evidence and Follow-up in Research

Across all indications, the research base primarily consists of studies designed to address short-term or episodic symptom patterns. These trials typically monitored responses over defined time intervals, such as one or two weeks. This focus means that the evidence provides insight into short-term changes but does not extensively evaluate outcomes over months or years. Consequently, long-term effects are not fully established, and there is limited information available regarding the sustained durability of any observed response or the frequency of symptom recurrence.

Key Studies & References

  1. NIH MedlinePlus on Glucocorticoids and Vasoconstrictors (Representative of pharmacological class confirmation)
  2. Randomized Controlled Trials (RCTs) on Topical Anesthetics and Corticosteroids for Anorectal Pain (Representative of primary clinical evidence used)

Frequently Asked Questions (FAQ)

Common questions about Anovate (FAQ)

Q: Does Anovate require a prescription?

Due to the presence of a potent corticosteroid (Beclometasone) and a local anesthetic (Lidocaine), Anovate is generally classified by regulatory authorities as a prescription-only medication. This classification is standard for medicines that require medical oversight and a confirmed diagnosis of the condition.


Q: Is Anovate considered a steroid medicine?

Anovate is a combination medication containing three different active components. One of these active ingredients, Beclometasone, is a type of medicine known as a corticosteroid, or steroid. The official product information notes this component is included for its ability to help reduce localized inflammation.


Q: How quickly does Anovate typically start working?

Official documents note that Anovate's benefit is the simultaneous mitigation of key symptoms, aimed at providing prompt, localized comfort. This is largely due to the presence of Lidocaine, a local anesthetic that is designed to rapidly affect pain signals. Symptomatic pain relief usually begins rapidly after the medicine is applied to the affected area.


Q: How long do the effects of Anovate usually last after applying it?

This specific duration is not usually detailed in general regulatory patient information. The official administration guidelines describe a variable frequency of use that is reduced as symptoms improve. This pattern indicates that the effects are generally expected to last between the recommended application times.


Q: Does Anovate cause dryness or irritation over time?

Localized effects such as irritation at the application site are common side effects reported in official documentation. Furthermore, the regulatory safety profile indicates that the risk of skin changes, such as skin atrophy or dryness, may increase with prolonged or extensive use of the cream.


Q: Is Anovate known to cause allergic reactions?

Official prescribing information strictly states that Anovate is prohibited for anyone with a known hypersensitivity or allergy to any of its components. While minor local reactions like stinging or irritation are common, a severe, systemic allergic reaction is possible, and signs of this should be discussed immediately with a healthcare professional.


Q: What are the signs of a severe reaction to Anovate?

Severe adverse reactions are rare but possible if too much medication is absorbed systemically, particularly from the Lidocaine component. Documented signs of systemic exposure include pale, gray, or blue-colored skin or lips (methemoglobinemia), extreme drowsiness, confusion, severe dizziness, or fainting.


Q: What are the restrictions on driving or operating machinery while using Anovate?

Official safety documentation notes potential nervous system side effects, such as dizziness or drowsiness, due to the topical anesthetic component. If an individual experiences these effects, regulatory information advises caution when driving or operating machinery.


Q: Do you need to wash your hands immediately after applying Anovate?

Regulatory guidelines describe the need for users to wash their hands thoroughly before and immediately after applying the cream. This practice helps prevent accidental transfer of the medication to other sensitive body parts or accidental ingestion.


Q: Can Anovate be used on sensitive skin areas?

Anovate is designed for the anal and rectal areas. Official regulatory information advises against its use on skin that has active infections caused by viruses, fungi, or bacteria. It is also prohibited for use on open wounds, ulcers, or broken skin in the area.


Q: Is it necessary to use a covering or bandage after applying Anovate?

The use of occlusive dressings, which are air-tight coverings or bandages, after applying the cream is generally not recommended. Official warnings state that occlusion can increase the risk of systemic absorption of the active components, particularly the steroid, which can lead to increased side effects.


Q: Does Anovate interact with common pain relievers like ibuprofen?

Because Anovate is applied topically, the risk of interaction is lower than with oral medications. However, official information describes that caution is needed, as the concurrent use of oral anti-inflammatory drugs like ibuprofen with the steroid component of Anovate carries a known, though rare, risk of gastrointestinal side effects.


Q: Are there any known interactions between Anovate and common supplements?

Specific interactions with common supplements are not typically itemized in official regulatory documents. However, because there is a potential for some of the active ingredients to be absorbed systemically, a review of all current supplements and herbal products with a healthcare professional is considered necessary.


Q: What should I do if I accidentally swallow a small amount of Anovate?

If the cream is accidentally swallowed, official regulatory information indicates that contacting emergency services or a poison control center is indicated. This is especially important if any signs of systemic exposure, such as severe dizziness, changes in heart rate, or confusion, are observed due to the local anesthetic component.


Q: What is the difference between the main active ingredient and the inactive ingredients in Anovate?

The active ingredients—Lidocaine, Beclometasone, and Phenylephrine—are the components that produce the therapeutic effects in the body. In contrast, the inactive ingredients serve specific purposes, such as forming the cream base, ensuring the product's stability, and aiding in the proper delivery of the active medicines.


Q: Does Anovate contain any parabens or common preservatives?

Yes, the official composition listed in regulatory documents includes the use of a common preservative. Specifically, the product contains Chlorocresol, which is added to ensure the product’s quality and shelf stability.


Q: Do other countries use Anovate for the same conditions?

The specific combination of a local anesthetic, a steroid, and a vasoconstrictor found in Anovate is a recognized formulation. This multi-component approach is used globally in various topical preparations for the symptomatic relief of hemorrhoids and related anorectal discomfort.

How should Anovate be stored and disposed of?

How to Store and Dispose of Anovate?

The official storage and disposal requirements for Anovate Cream are based on regulatory labeling to maintain product stability and ensure safe handling.

Storage Conditions

  • Temperature Control: The product must be stored at a temperature below 30°C and should not be frozen.
  • Environmental Protection: Storage is required in a dry place and away from direct sunlight.
  • Container Rules: The cap of the tube must be closed tightly after each use to protect the contents.
  • Child Safety: The medicine must be kept away from children and pets.

Disposal Instructions

Any unused or expired Anovate Cream, including all waste material, must be discarded properly. Disposal must follow all local requirements and regulations established for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Anovate found in:

A-Z Index: